Collaboration opportunity: bioactivities of natural products

Dear Colleagues,

This collaboration opportunity focuses on the identification and characterization of novel bioactivities of natural products (pure natural compounds, small molecules, plant extracts, enriched fractions). We will make use of already available natural products/extracts/bioassays available in house or at diverse national and international established collaboration partners, and we aim to get access to new natural products or new bioassays for bioactivity evaluation.

Who can participate in this collaborative work?

1. People who have interesting pure natural compounds, small molecules, plant extracts, or enriched fractions, and would like to offer them for testing with diverse assays for biological activity. In this case please supply a list with the samples that you would be interested to offer for testing.

2. People who have biological models suitable for bioactivity testing, and are interested in receiving samples for testing from others. In this case please supply information for the identity of the assay(s) that you offer, and the throughput capacity (how many samples approximately you are willing to test).

What are the conditions and the goals of this collaboration opportunity?

Within this research collaboration, each partner will cover their own research expenses (people supplying samples will cover the expenses related to sample delivery, and people performing the assays will cover expenses related to the running costs of the respective models).
The goals of this collaboration are the preparation of joint interdisciplinary research papers targeting impactful Q1-ranked journals, forming of consortiums for joint project proposals (upon the identification of suitable funding-calls), and maybe also joint patent applications or even joint start-up companies (in case of the identification of bioactivities with potentially high commercial value).

Please get in contact in case you are interested to join this research collaboration project. In addition to the requested above information, please also send a publication list (or link to your ResearchGate or GoogleScholar profile) – in order that we get a better overview for your previous experience. I am the main negotiation partner for this project, and your email should be addressed to me ( dongdong.wang@univie.ac.at ), with Dr. Atanasov on the CC ( a.atanasov.mailbox@gmail.com ).

With best wishes,
Dongdong Wang
https://www.researchgate.net/profile/Dongdong_Wang10




---

References
(5 selected collaborative research studies with Dr. Wang and/or Dr. Atanasov from 2016-2017)

Wang D, Tosevska A, Heiß EH, Ladurner A, Mölzer C, Wallner M, Bulmer A, Wagner KH, Dirsch VM, Atanasov AG. Bilirubin Decreases Macrophage Cholesterol Efflux and ATP-Binding Cassette Transporter A1 Protein Expression. J Am Heart Assoc. 2017 Apr 28;6(5). pii: e005520. doi: 10.1161/JAHA.117.005520. PubMed PMID: 28455345.
http://healthandscienceportal.blogspot.co.at/p/abstract-as-presented-by-authors-of_30.html

Vuorinen A, Engeli RT, Leugger S, Bachmann F, Akram M, Atanasov AG, Waltenberger B, Temml V, Stuppner H, Krenn L, Ateba SB, Njamen D, Davis RA, Odermatt A, Schuster D. Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2. J Nat Prod. 2017 Apr 28;80(4):965-974. doi: 10.1021/acs.jnatprod.6b00950. Epub 2017 Mar 20. PubMed PMID: 28319389; PubMed Central PMCID: PMC5411959.
http://healthandscienceportal.blogspot.co.at/p/abstract-as-presented-by-authors-of.html

Wang L, Palme V, Rotter S, Schilcher N, Cukaj M, Wang D, Ladurner A, Heiss EH, Stangl H, Dirsch VM, Atanasov AG. Piperine inhibits ABCA1 degradation and promotes cholesterol efflux from THP-1-derived macrophages. Mol Nutr Food Res. 2017 Apr;61(4). doi: 10.1002/mnfr.201500960. Epub 2016 Dec 23. PubMed PMID: 27862930; PubMed Central PMCID: PMC5382977.
https://www.ncbi.nlm.nih.gov/pubmed/27862930

Nguyen CH, Brenner S, Huttary N, Atanasov AG, Dirsch VM, Chatuphonprasert W, Holzner S, Stadler S, Riha J, Krieger S, de Martin R, Bago-Horvath Z, Krupitza G, Jäger W. AHR/CYP1A1 interplay triggers lymphatic barrier breaching in breast cancer spheroids by inducing 12(S)-HETE synthesis. Hum Mol Genet. 2016 Nov 15;25(22):5006-5016. doi: 10.1093/hmg/ddw329. PubMed PMID: 28171546.
https://www.ncbi.nlm.nih.gov/pubmed/28171546

Heiss EH, Liu R, Waltenberger B, Khan S, Schachner D, Kollmann P, Zimmermann K, Cabaravdic M, Uhrin P, Stuppner H, Breuss JM, Atanasov AG, Dirsch VM. Plumericin inhibits proliferation of vascular smooth muscle cells by blocking STAT3 signaling via S-glutathionylation. Sci Rep. 2016 Feb 9;6:20771. doi: 10.1038/srep20771. PubMed PMID: 26858089; PubMed Central PMCID: PMC4746734.
https://www.ncbi.nlm.nih.gov/pubmed/26858089